Literature DB >> 1500625

Imported fire ant immunotherapy: effectiveness of whole body extracts.

T M Freeman1, R Hylander, A Ortiz, M E Martin.   

Abstract

The purpose of this study was to determine if whole body extract (WBE) immunotherapy for imported fire ant (IFA) hypersensitivity is effective. This evaluation was carried out by retrospectively interviewing 76 patients with a history of generalized allergic reactions to IFA stings and positive skin tests to IFA-WBE. The study groups consisted of 65 patients on immunotherapy and 11 similar patients who were not treated for various reasons. In addition, an IFA sting challenge was performed in 30 volunteers of the 65 patients on immunotherapy. The retrospective review showed that of the 65 patients on immunotherapy there had been 112 subsequent field-sting episodes in 47 patients. Only one sting episode in this group (2.1%) produced an anaphylactic reaction. Six of the 11 patients not on immunotherapy have had subsequent field re-sting episodes, and each has had a systemic reaction. Repeat skin testing on 31 of the 65 patients in the immunotherapy group showed persistent positive responses in five (16%), but each was at a lower dilution than initially. Responses of the other 26 of the 31 patients who had skin testing had become negative. The four untreated patients who were available for skin testing continued to have positive responses at comparable dilutions on skin testing. Sting challenges carried out on 30 volunteers from the 65 patients (all from the 31 who had repeat skin tests) on immunotherapy resulted in only local reactions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500625     DOI: 10.1016/0091-6749(92)90073-b

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  Allergen Immunotherapy in Young Children.

Authors:  Venusa Phomakay; Mike Tankersley
Journal:  Curr Allergy Asthma Rep       Date:  2022-04-25       Impact factor: 4.919

2.  Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).

Authors:  Eric Leith; Tom Bowen; Joe Butchey; David Fischer; Harold Kim; Bill Moote; Peter Small; Don Stark; Susan Waserman
Journal:  Allergy Asthma Clin Immunol       Date:  2006-06-15       Impact factor: 3.406

Review 3.  Insect sting anaphylaxis.

Authors:  David B K Golden
Journal:  Immunol Allergy Clin North Am       Date:  2007-05       Impact factor: 3.479

4.  Anaphylaxis caused by stings from the Solenopsis invicta, lava-pés ant or red imported fire ant.

Authors:  Vidal Haddad Junior; Carlos Eduardo Larsson
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

5.  Worldwide perspectives on venom allergy.

Authors:  Peter Korošec; Thilo Jakob; Harfi Harb; Robert Heddle; Sarah Karabus; Ricardo de Lima Zollner; Julij Selb; Bernard Yu-Hor Thong; Fares Zaitoun; David B K Golden; Michael Levin
Journal:  World Allergy Organ J       Date:  2019-10-24       Impact factor: 4.084

Review 6.  Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?

Authors:  Cristoforo Incorvaia; Erminia Ridolo; Marina Mauro; Francesco Pucciarini; Enrico Heffler; Giorgio Walter Canonica
Journal:  Front Allergy       Date:  2022-02-16

Review 7.  Venom immunotherapy for preventing allergic reactions to insect stings.

Authors:  Robert J Boyle; Mariam Elremeli; Juliet Hockenhull; Mary Gemma Cherry; Max K Bulsara; Michael Daniels; J N G Oude Elberink
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 8.  Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management.

Authors:  Troy Wanandy; Emily Mulcahy; Wun Yee Lau; Simon G A Brown; Michael D Wiese
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-01       Impact factor: 8.667

9.  Management of insect sting hypersensitivity: an update.

Authors:  Robert D Pesek; Richard F Lockey
Journal:  Allergy Asthma Immunol Res       Date:  2013-02-25       Impact factor: 5.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.